1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Atox ‘Remains On Track’ Despite ACCUTE Setback

CEO Says Reltecimod NDA In NTSI Set For September

 
• By Sten Stovall

After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.

Wooden_Sign
Atox hopes to get FDA approval for reltecimod in NTSI by May 2021 • Source: Shutterstock

Atox Bio aims to submit an New Drug Application for its necrotizing soft tissue infections (NSTI) therapy to US regulators in September under the accelerated approval pathway there despite the drug missing a composite primary endpoint in a pivotal study, results from which have just been released, the biotech’s CEO told Scrip.

Atox’s lead asset reltecimod is being evaluated in a Phase III trial called ACCUTE, which stands for AB103 Clinical Composite...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Clinical Trials

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 
• By Alaric DeArment

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 
• By Alaric DeArment

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By Joseph Haas

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

More from R&D

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By Joseph Haas

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 
• By Alaric DeArment

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 
• By Andrew McConaghie

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.